AstraZeneca PLC

NASDAQ (USD): AstraZeneca PLC (AZN)

Last Price

71.20

Today's Change

+0.35 (0.49%)

Day's Change

70.68 - 71.47

Trading Volume

5,799,627

Overview

Market Cap

220 Billion

Shares Outstanding

3 Billion

Avg Volume

6,186,954

Avg Price (50 Days)

66.42

Avg Price (200 Days)

66.68

PE Ratio

37.67

EPS

1.89

Earnings Announcement

08-Feb-2024

Previous Close

70.85

Open

71.41

Day's Range

70.685 - 71.47

Year Range

60.47 - 75.75

Trading Volume

6,121,563

Price Change Highlight

1 Day Change

0.49%

5 Day Change

4.49%

1 Month Change

7.46%

3 Month Change

6.91%

6 Month Change

10.27%

Ytd Change

4.09%

1 Year Change

-6.08%

3 Year Change

35.96%

5 Year Change

83.88%

10 Year Change

106.32%

Max Change

1312.70%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Drug Manufacturers—General

Description:

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Discussions
Be the first to like this. Showing 3 of 3 comments

guppycrow

value buy stock

2020-06-16 01:30

WorldWideInvestor

Isnt this the vaccine maker?

2020-06-29 22:36

611385929

Thailand

2022-10-24 07:24

Post a Comment